Association between left ventricular hypertrophy and changes in arterial stiffness during hypertensive treatment. (July 2014)

• Record Type: Journal Article
• Authors: Masugata, Hisashi; Senda, Shoichi; Inukai, Michio; Himoto, Takashi; Hosomi, Naohisa; Murao, Koji; Okada, Hiroki; Goda, Fuminori
• Is Part Of: Clinical and experimental hypertension. Volume 36:Number 4(2014)
• Page Start: 258
• Page End: 262
• Publication Date: 2014-07
• Subjects: Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.3109/10641963.2013.810229
• Languages: English
• ISSNs: 1064-1963

Abstract

<abstract> <title>Abstract</title> <p>Cardio-ankle vascular index (CAVI) has been demonstrated as a parameter of arterial stiffness, which antihypertensive therapy may improve. However, little information is available about the factors affecting changes in arterial stiffness assessed by CAVI during antihypertensive therapy. We performed a study to examine the factors affecting changes in arterial stiffness assessed by CAVI during antihypertensive therapy. Eighty treated hypertensive patients (71 ± 10 years) were divided into two groups: 50 patients showing a decrease in CAVI (Group 1) and 30 patients showing an increase (Group 2) during observation (24 ± 11 months) of antihypertensive therapy. The groups did not differ in the rates of use of angiotensin II receptor blockers or calcium channel blockers. Age (Group 1: 67 ± 11 versus Group 2: 74 ± 8 years), left ventricular mass index (LVMI) (Group 1: 103 ± 19 versus Group 2: 120 ± 24 g/m<sup>2</sup>) and systolic blood pressure (Group 1: 133 ± 17 versus Group 2: 144 ± 23 mm Hg) at the start of observation were significantly higher in Group 2 than in Group 1 (<italic>p = </italic>0.003, <italic>p = </italic>0.001 and <italic>p = </italic>0.027, respectively). The changes in CAVI during observation were correlated only with LVMI (<italic>r = </italic>0.289, <italic>p = </italic>0.009) at the start of observation for all 80 patients. It may be difficult to improve arterial stiffness assessed by CAVI during antihypertensive therapy in hypertensive patients with left ventricular hypertrophy.</p> </abstract>